about
Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model.Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier modelsTargeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancementsImage-guided drug delivery to the brain using nanotechnology.In vivo transcranial cavitation threshold detection during ultrasound-induced blood-brain barrier opening in miceUltrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model.Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive propertiesProbing cocaine-antibody interactions in buffer and human serumCombinatorial approaches for the identification of brain drug delivery targets.Tumor necrosis factor α Inhibition for Alzheimer's Disease.Agile delivery of protein therapeutics to CNSDesign and characterization of structured protein linkers with differing flexibilities.Brain-penetrating tumor necrosis factor decoy receptor in the mouse.In vivo SELEX for Identification of Brain-penetrating Aptamers.Liver-targeting of interferon-alpha with tissue-specific domain antibodies.Pharmacokinetic characteristics, pharmacodynamic effect and in vivo antiviral efficacy of liver-targeted interferon alpha.Open challenges in magnetic drug targetingNeuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.Engaging neuroscience to advance translational research in brain barrier biology.Peptide derived from HIV-1 TAT protein destabilizes a monolayer of endothelial cells in an in vitro model of the blood-brain barrier and allows permeation of high molecular weight proteinsIn vivo and ex vivo regulation of breast cancer resistant protein (Bcrp) by peroxisome proliferator-activated receptor alpha (Pparα) at the blood-brain barrier.Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptorAn innovative approach to the treatment of Gaucher disease and possibly other metabolic disorders of the brain.Rapid and reversible enhancement of blood-brain barrier permeability using lysophosphatidic acid.Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting.SRL-Coated PAMAM Dendrimer Nano-Carrier for Targeted Gene Delivery to the Glioma Cells and Competitive Inhibition by Lactoferrin.Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.Genetic therapy for the nervous system.Improving the transport of chemotherapeutic drugs across the blood-brain barrier.Synthetic cell surface receptors for delivery of therapeutics and probes.Novel models for assessing blood-brain barrier drug permeation.Going further than Lipinski's rule in drug design.Fusion protein linkers: property, design and functionality.Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS.Peptide pills for brain diseases? Reality and future perspectives.Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases.Cell-penetrating Peptide-mediated therapeutic molecule delivery into the central nervous system.The blood-brain barrier: an engineering perspective.Nano-enabled delivery systems across the blood-brain barrier.
P2860
Q27316967-B022FB84-309D-4268-8E92-3040F37F0002Q28729033-178C6A43-1893-4DB9-BBCD-CC641CCA8C55Q30393215-B26E4B5A-ECCA-4770-B2F9-E0FBCF6B64A3Q30426990-36CBD591-89C9-44B3-B2C3-9A088A72E827Q30439400-CDA51568-D3CB-49B3-BB5D-C4B2C3A03675Q30447321-3A5E82F2-40BB-4456-8713-6BAE709B123DQ30572687-5A485F40-611A-4E1A-BFC0-DAD50A0A5D62Q31079066-9B937E38-507F-4AF0-BEE2-4DB12A6C4488Q31119779-033FF589-D3A3-476A-83F2-FD6DD2BE3480Q33704278-AAA22A28-BAAC-4541-907A-318307BBBE68Q34079647-5A45D0D2-CA0B-4BBF-BEAD-18CFED59891AQ34313196-6829B5F1-93A9-46FE-8952-C34B5C80F120Q34458394-C0671D90-0A84-4E01-8B92-AB580189434CQ34539526-F034DEED-1B0F-4731-B48A-87D93C72FF2BQ34603307-E6A6A9F8-84A7-4420-85A6-59D20B71B04BQ35090876-67E7D78F-D17B-4598-B33C-F06F09EE843DQ35417351-CB6DEE5B-B496-4D93-921C-5DB9FA080B83Q35429973-2C83F212-9F53-4D19-A1C9-E324E06931D3Q35909313-6F7EE144-02DB-463A-9BE0-6201167D01C0Q36492911-D17E4CC4-01C8-4819-B6DB-9CEE0C332C96Q36509809-637CAB7E-8245-4779-9677-3A65CAE2C25CQ36565901-47569A7A-CB48-4E4B-BB5C-04121FE5E2ABQ36566693-7A96171A-C572-49E8-96B4-278C03C7C83CQ37365650-DD434B00-A2C5-422E-82FB-76469D6E93D9Q37514889-40126DD9-F323-4A63-BC70-B9E30355EFC2Q37651101-06C09D9A-20DF-42CC-A106-D21460F6BF99Q37672410-6B45F95F-1A7C-4255-BE7F-9E02484DD7B0Q37856565-F3BA3BAF-1A9E-4F72-831F-7A65F13B8610Q37960529-5F62C2F7-DACA-4064-B033-6AFBC7F87536Q37991806-CA316AF3-6B9A-4974-8B6B-B0B14573F1DEQ37999058-EBA91D41-599A-403B-B715-07296DAE5B7FQ37999092-590B297F-F42B-430D-9B02-3F02C82233AAQ38048516-2A60D464-9E81-480E-A6F8-3F478E326C73Q38061448-9D1F64D3-B83C-498C-BCDB-8F467DF03C2FQ38073822-9C78D780-54E7-47AD-9270-EE4D8BA14242Q38096036-ABFB63A6-D55E-4A79-A700-7906DF8A524AQ38130176-8B7886B1-BAE7-4525-A3E8-2E1240284C69Q38133554-30336613-B82D-420D-B959-B5997B30DF29Q38134725-ED5543EB-31B8-4480-A02F-56AF5A6ED64AQ38156382-DD4930A3-D6C2-404E-B432-2B5B03AEF7B5
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biopharmaceutical drug targeting to the brain.
@en
Biopharmaceutical drug targeting to the brain.
@nl
type
label
Biopharmaceutical drug targeting to the brain.
@en
Biopharmaceutical drug targeting to the brain.
@nl
prefLabel
Biopharmaceutical drug targeting to the brain.
@en
Biopharmaceutical drug targeting to the brain.
@nl
P2860
P1476
Biopharmaceutical drug targeting to the brain.
@en
P2860
P304
P356
10.3109/10611860903548354
P577
2010-04-01T00:00:00Z